Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer

Cancer Gene Therapy

Volumn 9, Issue 11, 2002, Pages 935-945

  Bennett, Joseph J ^a   Delman, Keith A ^a   Burt, Bryan M ^a   Mariotti, Adam ^a   Malhotra, Sandeep ^a   Zager, Jonathan ^a   Petrowsky, Henrik ^a   Mastorides, Stephen ^a   Federoff, Howard ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gastric cancer; Gene therapy; Herpes simplex virus; HSV; Peritoneal cancer

Indexed keywords

ONCOLYTIC VIRUS; RIBONUCLEOTIDE REDUCTASE; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; CYTOTOXICITY; GENE DELETION; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PERITONEUM CANCER; PREDICTION; PRIORITY JOURNAL; SAFETY; STOMACH CANCER; TUMOR VOLUME; VIRAL GENE THERAPY; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS VIRULENCE; XENOGRAFT;

ANIMALS; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DISEASE-FREE SURVIVAL; ESCHERICHIA COLI; GENE THERAPY; GENETIC MARKERS; MICE; MICE, NUDE; SIMPLEXVIRUS; STOMACH NEOPLASMS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA; DNA VIRUSES; HERPESVIRIDAE; MURINAE; SIMPLEXVIRUS;

EID: 0036841571     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700510     Document Type: Article

References (46)

1. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854-856.
2. Jia WW, McDermott M, Goldie J, Cynader M, Tan J, Tufaro F. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1 (see comments). J Natl Cancer Inst. 1994;86:1209-1215.
3. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994;54:3963-3966.
4. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol. 1988;62:196-205.
5. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology. 1988;166:41-51.
6. Pyles RB, Thompson RL. Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J Virol. 1994;68:4963-4972.
7. Chambers R, Gillespie GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA. 1995;92:1411-1415.
8. Andreansky S, Soroceanu L, Flotte ER, et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997;57:1502-1509.
9. Kramm CM, Chase M, Herrlinger U, et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther. 1997;8:2057-2068.
10. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
11. Pyles RB, Wamick RE, Chalk CL, Szanti BE, Parysek LM. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther. 1997;8:533-544.
12. Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem. 1979;48:133-158.
13. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther. 2000;7:867-874.
14. Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J. 1999;6:499-504.
15. Bennett JJ, Kooby DA, Delman K, et al. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Ther. 2000;78:166-174.
16. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther. 1999;10:2237-2243.
17. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999;1:162-169.
18. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998;9:2177-2185.
19. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J Infect Dis. 1999;158:602-614.
20. Advani SJ, Chung SM, Yan SY, et al. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999;59:2055-2058.
21. Delman KA, Bennett JJ, Zager JS, et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther. 2000;11:2465-2472.
22. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs. 1999;7:137-149.
23. Kelsen D. Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol. 1999;23:379-389.
24. Averbach AM, Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg. 1999;83:726-733.
25. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1995;55:4752-4756.
26. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis. 1990;162:313-321.
27. Rosenberg SA, Anderson WF, Blaese M, et al. The development of gene therapy for the treatment of cancer. Ann Surg. 1993;218:455-463.
28. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis. 1999;14:43-54.
29. Yonemura Y, Yamguchi T, Fujimura T, et al. Mechanisms of the formation of the peritoneal dissemination in gastric cancer. Gastroenterology. 1999;56:785-802.
30. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999;5:881-887.
31. Kucharczuk JC, Randazzo B, Chang MY, et al. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res. 1997;57:466-471.
32. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 2000;14:301-311.
33. Sun WH, Stebler B, Ershler WB. Initial description of a tumor enhancing activity produced by murine splenocytes. Biochem Biophys Res Commun. 1991;179:675-682.
34. Roizman B. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA. 1996;93:11307-11312 (Review) (45 refs).
35. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Cancer. 1994;73:2048-2052.
36. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg. 1998;228:347-354.
37. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg. 1998;228:366-374 (published erratum appears in Ann Surg 1998:228(5) following table of contents).
38. Danthinne X, Aoki K, Kurachi AL, Nabel GJ, Nabel EG. Combination gene delivery of the cell cycle inhibitor p27 with thymidine kinase enhances prodrug cytotoxicity. J Virol. 1998;72:9201-9207.
39. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90:000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci USA. 1995;92:10516-10520.
40. He B, Gross M, Roizman B. The gamma 1(34.5) protein of herpes simplex virus 1 complexes with protein phosphatase lalpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA. 1997;94:843-848.
41. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA. 1992;89:3266-3270.
42. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene non-essential for growth in culture. Science. 1990;250:1262-1266.
43. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci USA. 2000;97:6097-6101.
44. Hunter WD, Martuza RL, Feigenbaum F, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J Virol. 1999;73:6319-6326.
45. Poffenberger KL, Tabares E, Roizman B. Characterization of a viable, noninverting herpes simplex virus 1 genome derived by insertion and deletion of sequences at the junction of components L and S. Proc Natl Acad Sci USA. 1983;80:2690-2694.
46. Suzuki T, Yanagi K, Ookawa K, Hatakeyama K, Ohshima N. Blood flow and leukocyte adhesiveness are reduced in the microcirculation of a peritoneal disseminated colon carcinoma. Ann Biomed Eng. 1998;26:803-811.